To educate oncology, managed care, and specialty pharmacists on optimal management of patients with advanced melanoma receiving immunotherapy, including ensuring appropriate access to patient-specific treatments, developing optimal toxicity prevention and management, and providing enhanced pharmaceutical care, thus leading to optimized outcomes.
At the conclusion of the continuing pharmacy education activities, the learner will be able to:
-Assess the efficacy and safety of current and emerging immunotherapy treatment strategies for advanced melanoma
-Discuss the role of immunotherapy in the management of metastatic melanoma to the brain
-Formulate strategies to effectively manage unique adverse events when using immunotherapy agents in the treatment of melanoma
This accredited activity has been designed for oncology, managed care and specialty pharmacist.